CHADDS FORD, Pa., May 26, 2011 /PRNewswire/ — Endo
Pharmaceuticals Holdings Inc. (NASDAQ:
ENDP) today announced a private offering of $700 million
aggregate principal amount of senior unsecured notes. The notes
will be unsecured, unsubordinated obligations of the Company and
will be guaranteed by certain of the Company’s subsidiaries.
Endo intends to use the net proceeds of this offering, together
with cash on hand and borrowings under its new credit facility, to
finance its acquisition of American Medical Systems Holdings, Inc.
(“AMS”), refinance Endo’s existing credit facility and existing AMS
indebtedness and pay related fees and expenses.
The notes and the related subsidiary guarantees have not been
registered under the Securities Act of 1933, as amended, or any
applicable state securities laws, and will be offered only to
qualified institutional buyers in reliance on Rule 144A, and
outside the United States in compliance with Regulation S under the
Securities Act. Unless so registered, the notes and the related
subsidiary guarantees may not be offered or sold in the United
States except pursuant to an exemption from the registration
requirements of the Securities Act and applicable state securities
laws. This press release will not constitute an offer to sell or a
solicitation of an offer to buy any notes or any other securities
of Endo.
Note:
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act and Section 21E of
the Securities Exchange Act of 1934, as amended (the “Exchange
Act”). These forward-looking statements include the following:
Endo’s intention to offer $700 million in aggregate principal
amount of notes and Endo’s intention regarding the use of the net
proceeds of the offering. These statements are
subject to
‘/>”/>
